

Luciano J Costa

List of Publications by Citations

Source: <https://exaly.com/author-pdf/173214/luciano-j-costa-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

153
papers

3,441
citations

29
h-index

57
g-index

164
ext. papers

4,501
ext. citations

4.2
avg, IF

5.01
L-index

#	Paper	IF	Citations
153	Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. <i>Blood</i> , 2011 , 118, 282-8	2.2	476
152	Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019 , 381, 727-738	59.2	266
151	Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 295-308	4.7	218
150	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. <i>Blood</i> , 2020 , 136, 936-945	2.2	189
149	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. <i>Leukemia</i> , 2019 , 33, 2266-2275	10.7	188
148	Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. <i>Blood Advances</i> , 2017 , 1, 282-287	7.8	164
147	Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1262-73	4.7	130
146	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 859-866	2.2	100
145	Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 89-97	4.7	99
144	Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1615-24	4.7	85
143	Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1729-36	4.7	79
142	Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 402-408.e1	4.7	79
141	First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial. <i>Blood</i> , 2019 , 134, 143-143	2.2	76
140	Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. <i>Blood</i> , 2013 , 121, 4861-6	2.2	61
139	Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2019 , 124, 2119-2119	2.2	57
138	Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3320-8	1.9	53
137	Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 701-6	4.7	51

136	R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. <i>British Journal of Haematology</i> , 2018 , 180, 534-544	4.5	48
135	Impact of marital status, insurance status, income, and race/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States. <i>Cancer</i> , 2016 , 122, 3183-3190	6.4	44
134	Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. <i>American Journal of Hematology</i> , 2017 , 92, 161-170	7.1	43
133	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1746-53	4.7	39
132	Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. <i>Cancer</i> , 2017 , 123, 3141-3149	6.4	38
131	Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2827-2832	1.9	38
130	Nonbiological factors affecting survival in younger patients with acute myeloid leukemia. <i>Cancer</i> , 2015 , 121, 3877-84	6.4	35
129	Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2020 , 6, 1759-1765	13.4	34
128	Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1543-1551	4.7	34
127	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , 2021 , 22, e105-e118	21.7	32
126	Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara-Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT). <i>Blood</i> , 2018 , 132, 151-151	2.2	31
125	Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 951-9	4.7	30
124	Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 222-8	4.7	29
123	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. <i>Leukemia</i> , 2021 , 35, 18-30	10.7	29
122	Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 909-913	4.7	27
121	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 73-85	4.7	25
120	Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. <i>Transfusion</i> , 2012 , 52, 2375-81	2.9	24
119	Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 645-9	1.9	23

118	Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 798-804	4.7	22
117	Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features. <i>Cancer Causes and Control</i> , 2016 , 27, 81-91	2.8	21
116	Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1810-1816	4.4	21
115	C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. <i>Cancer</i> , 2017 , 123, 4411-4418	6.4	19
114	Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 71	22.4	17
113	Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2016 , 91, 101-8	7.1	16
112	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 269-277	4.7	15
111	Second primary malignancy after multiple myeloma-population trends and cause-specific mortality. <i>British Journal of Haematology</i> , 2018 , 182, 513-520	4.5	14
110	Safety and Efficacy Of Obinutuzumab (GA101) Plus CHOP Chemotherapy In First-Line Advanced Diffuse Large B-Cell Lymphoma: Results From The Phase 2 Gather Study (GAO4915g). <i>Blood</i> , 2013 , 122, 1820-1820	2.2	14
109	Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101935	2.2	13
108	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. <i>Blood</i> , 2020 , 136, 45-46	2.2	13
107	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1197-1205	4.7	12
106	Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1379-1385	4.7	11
105	A Phase I/II Trial Of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) In Patients With Newly Diagnosed Multiple Myeloma: Final Results Of MTD Expansion Cohort. <i>Blood</i> , 2013 , 122, 3179-3179	2.2	11
104	Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Blood Advances</i> , 2021 , 5, 3748-3759	7.8	11
103	Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 351-357	2	10
102	Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 552-8	4.7	9
101	Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021 , 138, 158-158	2.2	9

100	Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, e7-e15	4.7	9
99	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. <i>American Journal of Hematology</i> , 2021 , 96, E5-E8	7.1	9
98	Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study. <i>Blood</i> , 2021 , 138, 157-157	2.2	8
97	Defining and Managing High-Risk Multiple Myeloma: Current Concepts. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1730-1737	7.3	8
96	Changes in the use of radiation therapy for early classical Hodgkin lymphoma in adolescents and young adults: implications for survival and second malignancies. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2339-43	1.9	7
95	Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange. <i>European Journal of Haematology</i> , 2012 , 89, 432-4	3.8	7
94	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. <i>Blood</i> , 2018 , 132, 2015-2015	2.2	7
93	A phase I/II trial of cyclophosphamide, carfilzomib, thalidomide, and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8010-8010	2.2	7
92	Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. <i>Leukemia and Lymphoma</i> , 2019 , 60, 894-903	1.9	7
91	Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab?. <i>Cancer Medicine</i> , 2020 , 9, 5519-5525	4.8	6
90	Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making. <i>American Journal of Hematology</i> , 2016 , 91, 1044-51	7.1	6
89	Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma. <i>British Journal of Haematology</i> , 2019 , 186, 807-819	4.5	6
88	Results From the Phase II Dose Expansion of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2012 , 120, 445-445	2.2	6
87	Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 233-238	4.7	6
86	Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 264.e1-264.e7		6
85	Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma. <i>Cancer Control</i> , 2015 , 22, 87-94	2.2	5
84	Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2009 , 50, 781-7	1.9	5
83	Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment. <i>Blood</i> , 2018 , 132, 3233-3233	2.2	5

82	Incidence and outcomes of rare paediatric non-hodgkin lymphomas. <i>British Journal of Haematology</i> , 2019 , 184, 864-867	4.5	5
81	Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults. <i>American Journal of Hematology</i> , 2018 , 93, 238-245	7.1	5
80	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1744-1755	4.7	4
79	Early Mortality in Multiple Myeloma: Risk Factors and Impact on Population Outcomes. <i>Blood</i> , 2014 , 124, 1320-1320	2.2	4
78	Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. <i>Blood Advances</i> , 2021 , 5, 1092-1096	7.8	4
77	New regimens and directions in the management of newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2021 , 96, 367-378	7.1	4
76	Cost-Effective Use of Plerixafor for Hematopoietic Stem Cells Mobilization: Development and Validation of a Decision-Making Algorithm.. <i>Blood</i> , 2009 , 114, 3216-3216	2.2	3
75	Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. <i>Leukemia</i> , 2021 ,	10.7	3
74	Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow. <i>Leukemia Research</i> , 2018 , 74, 64-67	2.7	3
73	Enrolment of racial minorities across 15 years of multiple myeloma randomised trials; calling on researchers to become agents of change. <i>Lancet Haematology,the</i> , 2020 , 7, e704-e706	14.6	2
72	Impact of Autologous Hematopoietic Stem Cell Transplant (AHCT) on Measurable Residual Disease (MRD) By Next Generation Sequencing (NGS) in the Setting of Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Quadruplet Induction.. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, S24	4.7	2
71	Incidence and outcomes of paediatric myelodysplastic syndrome in the United States. <i>British Journal of Haematology</i> , 2018 , 180, 898-901	4.5	2
70	Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1345-1348	4.4	2
69	Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone. <i>Blood</i> , 2020 , 136, 415	2.2	2
68	Proteomic Analysis of Plasma Exosome-Associated Proteins Reveals That Differences In Kappa:Lambda Ratios Predict Severe Acute Graft-Versus-Host Disease Early After Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2010 , 116, 1278-1278	2.2	2
67	Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012 , 120, 3933-3933	2.2	2
66	Post-Transplant Therapy Is More Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM). <i>Blood</i> , 2015 , 126, 396-396	2.2	2
65	High Dose Fractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (mHyperCVAD) Is an Active Regimen in Heavily Pretreated Relapsed/Refractory Multiple Myeloma, Enabling Access to Experimental Therapies. <i>Blood</i> , 2021 , 138, 3784-3784	2.2	2

64	Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy. <i>Lancet Haematology,the</i> , 2021 , 8, e386-e387	14.6	2
63	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019 , 60, 940-946	1.9	2
62	LEAM versus CBV for conditioning in autologous hematopoietic stem cell transplantation for lymphoma. <i>Bone Marrow Transplantation</i> , 2019 , 54, 625-628	4.4	2
61	Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1364-1372	4.4	2
60	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. <i>Blood Cancer Discovery</i> , OF1-OF12	7	2
59	Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivors. <i>Leukemia Research</i> , 2019 , 82, 1-6	2.7	1
58	Fewer scans, better care. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1624	2.2	1
57	Real-World Applicability of Commercial Chimeric Antigen Receptor T Cell Therapy Among Older Adults with Relapsed and/or Refractory Multiple Myeloma.. <i>American Journal of Hematology</i> , 2022 ,	7.1	1
56	Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies. <i>Blood</i> , 2018 , 132, 3303-3303	2.2	1
55	Temporal Trends in Early Mortality in Acute Promyelocytic Leukemia in the United States. <i>Blood</i> , 2018 , 132, 710-710	2.2	1
54	Comparison Between Pegfilgrastim and Filgrastim-Based Autologous Hematopoietic Stem Cell Mobilization in the Setting of Patient Adapted (Just in Time) Plerixafor: Efficacy and Cost Analysis. <i>Blood</i> , 2011 , 118, 1921-1921	2.2	1
53	Sphingolipids As a Novel Target For The Treatment Of Multiple Myeloma. <i>Blood</i> , 2013 , 122, 3163-3163	2.2	1
52	Phase 1 Trial Of Carfilzomib + High Dose Melphalan Conditioning Regimen Prior To Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Relapsed Multiple Myeloma. <i>Blood</i> , 2013 , 122, 3329-3329	2.2	1
51	Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation. <i>Blood</i> , 2014 , 124, 2447-2447	2.2	1
50	Pegfilgrastim 6 Mg Versus 12 Mg for Autologous Stem Cell Mobilization in Multiple Myeloma Patients: Efficacy, Safety, and Cost Analysis. <i>Blood</i> , 2015 , 126, 4306-4306	2.2	1
49	Expression of Epstein-Barr Virus in Cell of Classical Hodgkin's Lymphoma Tumor. <i>Blood</i> , 2016 , 128, 5358-5358	1	1
48	Preliminary Results of a Phase 2 Study of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2011 , 118, 2940-2940	2.2	1
47	Treatments for newly diagnosed multiple myeloma: when endurance is interrupted. <i>Lancet Oncology, The</i> , 2020 , 21, e540	21.7	1

46	Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: A US population-based study. <i>American Journal of Hematology</i> , 2021 , 96, E265-E268	7.1	1
45	Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma. <i>British Journal of Haematology</i> , 2021 , 195, e113-e116	4.5	1
44	Up-front autologous hematopoietic stem cell transplantation (AHSCT) from a single Brazilian center. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1181-1183	4.4	1
43	Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis. <i>Journal of Geriatric Oncology</i> , 2021 , 12, 256-261 ^{3,6}	3.6	1
42	Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 55.e1-55.e7		1
41	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , 2021 , 21, 993	4.8	1
40	How I treat triple-class refractory multiple myeloma.. <i>British Journal of Haematology</i> , 2022 ,	4.5	1
39	Autologous and allogeneic progenitor cell mobilization 2017 , 45-52		0
38	Associaçã Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients. <i>Hematology, Transfusion and Cell Therapy</i> , 2021 , 43 Suppl 2, S30-S34	1.6	0
37	Most Patients with Core Binding Factor AML Require Hematopoietic Stem Cell Transplantation for Long-Term Survival: Long Term Follow-up of a Cohort of Unselected Patients.. <i>Blood</i> , 2010 , 116, 4560-4560 ^{2,2}	2.2	0
36	Impact of insurance status on the survival of younger patients diagnosed with acute promyelocytic leukemia in the United States. <i>Cancer</i> , 2021 , 127, 2966-2973	6.4	0
35	Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation. <i>American Journal of Hematology</i> , 2021 , 96, E396-E398	7.1	0
34	Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. <i>Expert Review of Hematology</i> , 2021 , 1-16	2.8	0
33	Reduction in Late Mortality Among Patients With Multiple Myeloma Treated With Autologous Peripheral Blood Stem Cell Transplantation-A Blood or Marrow Transplant Survivor Study Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 840.e1-840.e7		0
32	Reply to a note on the magnitude of hazard ratios. <i>Cancer</i> , 2016 , 122, 1299-300	6.4	
31	Role of Neutrophil Lymphocyte Ratio [NLR] As a Biomarker of Frailty and Predictor of Survival Among Older Adults with Multiple Myeloma (MM). <i>Blood</i> , 2020 , 136, 6-6	2.2	
30	Maximum-tolerated dose of lomustine used in combination with etoposide and cyclophosphamide in conditioning regimen for hematopoietic stem cell transplantation in lymphoma patients. <i>Bone Marrow Transplantation</i> , 2021 ,	4.4	
29	Managing Multiple Myeloma in Older Adults Using Real World Evidence and Clinical Integration of a Geriatric Assessment Tool in Clinical Practice. <i>Blood</i> , 2021 , 138, 5019-5019	2.2	

28	Nonbiological Factors Affecting Outcomes in Adolescent and Young Adults with Lymphoma. <i>Blood</i> , 2018 , 132, 4857-4857	2.2
27	Evaluation of Pre-Collection Factors and Collection Efficiency Leads to Strong Correlation between Predicted and Actual Peripheral Blood Stem Cell Collection Yields in Multiple Myeloma Patients: A Single Institution Experience. <i>Blood</i> , 2018 , 132, 3349-3349	2.2
26	Disparities in Utilization of Autologous Hematopoietic Progenitor Cell Transplantation for Multiple Myeloma in the US. <i>Blood</i> , 2014 , 124, 557-557	2.2
25	Induction Therapy with Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplantation for Systemic Light Chain Amyloidosis: Our Experience. <i>Blood</i> , 2014 , 124, 5907-5907	2.2
24	Demographic Differences Between Unselected Patients and Participants of Multiple Myeloma Clinical Trials in the US: A Threat to External Validity. <i>Blood</i> , 2015 , 126, 634-634	2.2
23	Insurance Status, Marital Status and Income, but Not Race-Ethnicity Affect Outcomes of Younger Patients Diagnosed with Multiple Myeloma in the US. <i>Blood</i> , 2015 , 126, 633-633	2.2
22	Excessive Rate of Late Infections and Treatment Related Mortality Associated with the Use of Alemtuzumab in Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Trial.. <i>Blood</i> , 2009 , 114, 2230-2230	2.2
21	Dual Inhibition of mTOR and Pim Kinase Pathways Using Small Molecule Inhibitors Synergistically Kills Myeloid Leukemic Cells In Vitro and In Vivo.. <i>Blood</i> , 2010 , 116, 293-293	2.2
20	Extended Use of Ciprofloxacin Markedly Decreases the Incidence of Severe BK Virus-Associated Hemorrhagic Cystitis In Allogeneic HSCT Recipients. <i>Blood</i> , 2010 , 116, 2317-2317	2.2
19	Association of Age with Fluorescence In Situ Hybridization (FISH) Abnormalities In Multiple Myeloma Patients Reveals Higher Rate of Igh Translocations Among Older Patients. <i>Blood</i> , 2010 , 116, 1913-1913	2.2
18	Effects of Method of Peripheral Blood Hematopoietic Stem Cell Mobilization (G-CSF, G-CSF + Plerixafor, or Cyclophosphamide + G/GM-CSF) on Engraftment and Sustained Graft Function: Comparison Across Cohorts with Similar CD34+ Cell Dose. <i>Blood</i> , 2010 , 116, 2255-2255	2.2
17	High-Dose Cyclophosphamide Is An Effective Salvage Therapy for High-Risk Multiple Myeloma Refractory to New Biological Agents. <i>Blood</i> , 2010 , 116, 5041-5041	2.2
16	Race, Access to Care, and Outcome After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. <i>Blood</i> , 2010 , 116, 1509-1509	2.2
15	Potential Use of Sphingosine Kinase-2 Selective Inhibitors for the Treatment of Multiple Myeloma. <i>Blood</i> , 2011 , 118, 5105-5105	2.2
14	Characterization of Pim Protein Kinases and Evaluation of Small Molecule Inhibitors in Multiple Myeloma. <i>Blood</i> , 2011 , 118, 2909-2909	2.2
13	Regulation and Functional Role of Beta2-Adrenergic Receptor in Acute Myelogenous Leukemia. <i>Blood</i> , 2011 , 118, 2563-2563	2.2
12	Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America. <i>Blood</i> , 2012 , 120, 813-813	2.2
11	Trends in Survival of Patients with Burkitt Lymphoma Diagnosed in the USA: An Analysis of 3691 Cases. <i>Blood</i> , 2012 , 120, 761-761	2.2

10	The Influence of Race and ADAMTS13 Status On Outcomes in Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2012 , 120, 4638-4638	2.2
9	Risk and Outcome of Non-Hodgkin Lymphoma Among Hodgkin Lymphoma Survivors: Analysis From the Surveillance, Epidemiology and End Results (SEER) Registry.. <i>Blood</i> , 2012 , 120, 2639-2639	2.2
8	Trends in Utilization and Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) in the Upfront Management of Patients with Multiple Myeloma: A CIBMTR Analysis. <i>Blood</i> , 2012 , 120, 596-596	2.2
7	Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America. <i>Blood</i> , 2013 , 122, 768-768	2.2
6	Changes In The Use Of Radiation Therapy Among Adolescents and Young Adults With Early Stage Classical Hodgkin Lymphoma: Implications For Survival and Risk Of Secondary Malignancies. <i>Blood</i> , 2013 , 122, 722-722	2.2
5	Similar Dynamics Of Intra Apheresis Autologous CD34+ Recruitment and Collection Efficiency In Patients Undergoing Mobilization With Or Without Plerixafor. <i>Blood</i> , 2013 , 122, 904-904	2.2
4	Population Outcomes Of Primary Mediastinal Large B-Cell Lymphoma In The Rituximab Era. <i>Blood</i> , 2013 , 122, 1743-1743	2.2
3	Excessive Early Mortality Drives Poor Long Term Outcomes Among Older Patients With Classical Hodgkin Lymphoma: A Population Study. <i>Blood</i> , 2013 , 122, 1742-1742	2.2
2	Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma-Reply. <i>JAMA Oncology</i> , 2021 , 7, 635-636	13.4
1	Leveraging minimal residual disease to reassess autologous hematopoietic cell transplantation in multiple myeloma. <i>Advances in Cell and Gene Therapy</i> , 2021 , 4, e97	1.2